• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Procept Biorobotics Corp (NQ: PRCT )

    58.80 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 58.80
    Bid (Size) 58.60 (1)
    Ask (Size) 61.34 (1)
    Prev. Close 58.80
    Today's Range 58.80 - 58.80
    52wk Range 24.83 - 77.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
    From PROCEPT BioRobotics
    Via GlobeNewswire

    Performance

    YTD
    +41.89%
    +41.89%
    1 Month
    -8.81%
    -8.81%
    3 Month
    +26.64%
    +26.64%
    6 Month
    +37.74%
    +37.74%
    1 Year
    +72.89%
    +72.89%

    More News

    Read More
    From Science Fiction to Reality: 3 Robotics Stocks for Automatic Riches
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
    From PROCEPT BioRobotics
    Via GlobeNewswire
    Unveiling 4 Analyst Insights On PROCEPT BioRobotics
    Via Benzinga
    Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
    From PROCEPT BioRobotics
    Via GlobeNewswire
    Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
    Via Investor's Business Daily
    PRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics: Q4 Earnings Insights
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    PROCEPT BioRobotics's Earnings: A Preview
    Via Benzinga
    Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
    From PROCEPT BioRobotics
    Via GlobeNewswire
    Demystifying PROCEPT BioRobotics: Insights From 4 Analyst Reviews
    Via Benzinga
    PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
    From PROCEPT BioRobotics
    Via GlobeNewswire
    Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know
    Via Benzinga
    PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
    From PROCEPT BioRobotics
    Via GlobeNewswire
    Procept BioRobotics Shares Are Higher Today, CEO Touts 'Strong Surgeon Interest'
    Via Benzinga
    PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics Stock Scores Rising Relative Strength
    Via Investor's Business Daily
    PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
    From PROCEPT BioRobotics
    Via GlobeNewswire
    PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
    From PROCEPT BioRobotics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.